Research Proposal Sample for Nurses

INSTITUTIONAL RESEARCH SERVICES & CLINICAL PROTOCOL AGREEMENT

Document ID: IRD-2026-NURSE-089A
Effective Date: [Effective Date]
Version: 4.2 (Institutional Grade)
Governing Jurisdiction: [State/Country]

---

1. STATUTORY & LEGAL COMPLIANCE NOTICE

CLINICAL AND LEGAL DISCLAIMER: This document constitutes a binding legal framework governing clinical nursing research, data acquisition, and institutional obligations. The parties acknowledge that clinical research conducted under this Agreement must strictly adhere to all applicable federal, state, and local statutes, including but not limited to the Health Insurance Portability and Accountability Act (HIPAA), the Common Rule (45 CFR 46), Food and Drug Administration (FDA) regulations governing Good Clinical Practice (GCP), and Institutional Review Board (IRB) mandates. Legal enforceability of clinical protocols requires proper institutional authorization, regulatory clearance, and execution by duly authorized representatives of all participating entities.

---

2. PARTIES & RECITALS

This Institutional Research Services & Clinical Protocol Agreement (the "Agreement") is entered into and made effective as of [Effective Date] (the "Effective Date"), by and between:

Research Institution / Sponsor: [Company Full Legal Name], having its principal place of business at [Principal Address] (hereinafter referred to as the "Institution"), and

Principal Investigator / Lead Nurse Researcher: [Client Full Legal Name], residing or having a professional office at [Principal Address] (hereinafter referred to as the "Researcher").

WHEREAS, the Institution desires to retain the professional services of the Researcher to design, execute, and administer a clinical nursing research protocol; and
WHEREAS, the Researcher possesses the requisite clinical licensing, academic credentials, and professional expertise to perform such research services in accordance with the highest standards of clinical practice;

NOW, THEREFORE, in consideration of the mutual covenants, promises, and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

---

3. EXHAUSTIVE OPERATIVE CLAUSES & LEGAL TERMS

SECTION 1: SCOPE OF SERVICES & ENGAGEMENT

1.1 Engagement: The Institution hereby engages the Researcher, and the Researcher hereby accepts such engagement, to independently perform, manage, and complete the clinical research study entitled [Insert Exact Study Title] (the "Project"), as detailed in the Research Proposal annexed hereto as Exhibit A and incorporated herein by this reference.

1.2 Professional Standards: The Researcher shall perform all services under this Agreement with the highest degree of professional care, skill, and diligence practiced by nationally recognized clinical nurse researchers. All work shall comply strictly with the approved IRB protocol, applicable institutional policies, and all governing federal and state healthcare regulations.

1.3 Deliverables: The Researcher shall deliver comprehensive research milestones, including but not limited to preliminary data analysis reports, interim safety monitoring reports, the finalized clinical research manuscript, and all raw datasets (appropriately de-identified), strictly in accordance with the timeline set forth in Schedule 1 of this Agreement.

SECTION 2: COMPENSATION & PAYMENT TERMS

2.1 Total Compensation: In full consideration for the services rendered by the Researcher under this Agreement, the Institution shall pay the total sum of [Amount in USD] USD (the "Contract Price"), payable in milestone installments as specified in Schedule 2.

2.2 Invoicing & Payment Schedule: The Researcher shall submit detailed, itemized invoices to the Institution upon the successful completion and institutional sign-off of each designated milestone. The Institution shall remit payment within thirty (30) days of receipt of a compliant invoice. All payments shall be made via electronic wire transfer or check to the designated banking account provided by the Researcher.

2.3 Late Payment & Interest: Any invoice amount not paid when due shall accrue interest at the lesser of one and one-half percent (1.5%) per month or the maximum rate permitted by applicable law, calculated from the date such payment was due until the date paid in full.

2.4 Expenses: Unless expressly authorized in advance and in writing by the Institution, the Researcher shall be solely responsible for all costs and expenses incurred in the performance of this Agreement, including travel, supplies, and administrative overhead.

SECTION 3: TERM & TERMINATION

3.1 Term: This Agreement shall commence on the Effective Date and shall continue in full force and effect until [Insert Termination Date] or until the Project is fully completed and accepted by the Institution, unless terminated earlier in accordance with this Section 3.

3.2 Termination for Convenience: The Institution may terminate this Agreement, in whole or in part, at any time for any reason or no reason, by providing thirty (30) days prior written notice to the Researcher. Upon receipt of such notice, the Researcher shall immediately cease all non-essential research activities and take all necessary steps to mitigate costs.

3.3 Termination for Cause: Either party may terminate this Agreement immediately upon written notice if the other party materially breaches any provision of this Agreement and fails to cure such material breach within thirty (30) days of receiving written notice specifying the breach. Material breach shall include, without limitation, any ethical violation, loss of nursing licensure, clinical misconduct, or breach of confidentiality.

3.4 Effect of Termination: Upon termination, the Researcher shall promptly deliver to the Institution all work product, data, records, and biological or informational materials collected or generated up to the date of termination. The Institution shall pay the Researcher for all legitimate services rendered and approved expenses incurred up to the effective date of termination, calculated on a pro-rata milestone basis.

SECTION 4: INTELLECTUAL PROPERTY OWNERSHIP & WORK MADE FOR HIRE

4.1 Work Made for Hire: The parties agree that all research data, clinical notes, statistical analyses, interim drafts, final manuscripts, and associated intellectual property developed by the Researcher pursuant to this Agreement (collectively, the "Work Product") shall be considered a "work made for hire" exclusively for the Institution under the copyright laws of the United States.

4.2 Assignment of Rights: To the extent that any Work Product does not qualify as a work made for hire, the Researcher hereby irrevocably assigns, transfers, and conveys to the Institution all right, title, and interest worldwide in and to such Work Product, including all copyrights, patents, trademarks, and trade secret rights.

4.3 Researcher Pre-Existing IP: The Researcher retains sole ownership of any proprietary methodologies, pre-existing software, or generic templates developed independently of this Agreement (the "Pre-Existing IP"). The Researcher grants the Institution a perpetual, irrevocable, royalty-free, worldwide license to use such Pre-Existing IP solely as incorporated into or necessary for the utilization of the Work Product.

SECTION 5: MUTUAL CONFIDENTIALITY & NON-DISCLOSURE

5.1 Definition of Confidential Information: "Confidential Information" includes all non-public information, data, patient records, proprietary formulas, trade secrets, business strategies, and clinical protocols disclosed by one party (the "Disclosing Party") to the other party (the "Receiving Party") in connection with this Agreement, whether orally or in writing.

5.2 Obligations of Confidentiality: The Receiving Party shall hold all Confidential Information in strict confidence, using the same degree of care it uses to protect its own proprietary information (but no less than reasonable care). The Receiving Party shall not disclose Confidential Information to any third party without the prior written consent of the Disclosing Party, except to employees, legal counsel, and institutional review boards who have a direct need to know and are bound by confidentiality obligations at least as restrictive as those herein.

5.3 Exclusions: Confidential Information shall not include information that: (a) is or becomes publicly known through no breach of the Receiving Party; (b) was already known to the Receiving Party prior to disclosure; (c) is independently developed by the Receiving Party without reference to the Disclosing Party's Confidential Information; or (d) is required to be disclosed by law, court order, or regulatory mandate, provided the Receiving Party gives prompt written notice to the Disclosing Party.

SECTION 6: REPRESENTATIONS & WARRANTIES

6.1 Researcher Warranties: The Researcher represents and warrants that:

• (a) They possess the active, unencumbered nursing licensure, credentials, and institutional privileges required to perform the Project;
• (b) They have not been debarred, suspended, or excluded from participation in federal healthcare programs;
• (c) All research will be conducted with strict adherence to ethical standards, human subject protections (IRB approval), and scientific integrity; and
• (d) The Work Product is original and does not infringe upon the intellectual property or privacy rights of any third party.

6.2 Institution Warranties: The Institution represents and warrants that it has the full legal authority to enter into this Agreement, fund the Project, and secure all necessary regulatory approvals required for the lawful execution of the clinical protocol.

SECTION 7: LIMITATION OF LIABILITY & INDEMNIFICATION

7.1 Limitation of Liability: Except for liability arising from breaches of confidentiality, intellectual property infringement, or gross negligence/willful misconduct, neither party shall be liable to the other for any indirect, incidental, consequential, special, or punitive damages, including loss of profits or institutional revenue, arising out of or in connection with this Agreement.

7.2 Researcher Indemnification: The Researcher shall defend, indemnify, and hold harmless the Institution, its officers, directors, agents, and employees from and against any and all claims, liabilities, losses, damages, or costs (including reasonable attorneys' fees) arising out of or resulting from the Researcher’s gross negligence, willful misconduct, professional malpractice, or material breach of this Agreement.

7.3 Institution Indemnification: The Institution shall defend, indemnify, and hold harmless the Researcher from and against any claims, liabilities, losses, damages, or costs arising out of the Institution’s institutional negligence, breach of this Agreement, or claims arising from the clinical administration of products or protocols mandated by the Institution.

SECTION 8: DISPUTE RESOLUTION & ARBITRATION

8.1 Good Faith Negotiation: In the event of any dispute, controversy, or claim arising out of or relating to this Agreement, the designated representatives of the parties shall first attempt to resolve the matter amicably through good-faith negotiations for a period of thirty (30) days.

8.2 Binding Arbitration: If the dispute remains unresolved following the 30-day negotiation period, the matter shall be submitted to binding arbitration administered by the American Arbitration Association (AAA) in accordance with its Commercial Arbitration Rules. The arbitration shall be conducted by a single neutral arbitrator in [City, State]. The award rendered by the arbitrator shall be final and binding, and judgment upon the award may be entered in any court having jurisdiction thereof.

SECTION 9: GOVERNING LAW & JURISDICTION

9.1 This Agreement, and all claims or causes of action (whether in contract, tort, or statute) that may be based upon, arise out of, or relate to this Agreement, shall be governed by, enforced under, and construed in accordance with the internal laws of the State of [State], without regard to its conflict of laws principles. The parties irrevocably submit to the exclusive jurisdiction of the state and federal courts located within [County, State] for any legal proceedings permitted under Section 8.

SECTION 10: MISCELLANEOUS

10.1 Severability: If any provision of this Agreement is held to be invalid, illegal, or unenforceable by a court or arbitrator of competent jurisdiction, such provision shall be modified to the minimum extent necessary to make it valid and enforceable, and the remaining provisions of this Agreement shall remain in full force and effect.

10.2 Counterparts: This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Execution may be accomplished via facsimile, PDF, or secure electronic signature platforms (e.g., DocuSign).

10.3 Entire Agreement: This Agreement, together with any attached Exhibits, Schedules, and Research Proposals, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous discussions, negotiations, proposals, or agreements, whether written or oral. No modification, amendment, or waiver of any provision of this Agreement shall be effective unless set forth in a writing signed by authorized representatives of both parties.

---

4. EXECUTION & FORMAL SIGNATURE BLOCKS

IN WITNESS WHEREOF, the parties hereto have caused this Institutional Research Services & Clinical Protocol Agreement to be duly executed by their respective authorized signatories as of the Effective Date written above.

FOR [COMPANY FULL LEGAL NAME] (RESEARCH INSTITUTION):
Signature: _____________________________________
Printed Name: [Authorized Signatory Name]
Title: [Title / Role]
Company: [Company Legal Name]
Date: [Date]

FOR [CLIENT FULL LEGAL NAME] (PRINCIPAL RESEARCHER):
Signature: _____________________________________
Printed Name: [Authorized Signatory Name]
Title: [Title / Role]
Date: [Date]

---

5. STEP-BY-STEP EXECUTION & FILING GUIDE

1. Document Customization (Word Processing Phase):

   • Open this document in Microsoft Word, Google Docs, or an equivalent legal word processor.
   • Use the Find and Replace function to locate all bracketed variables (e.g., [Company Full Legal Name], [Client Full Legal Name], [Principal Address], [Effective Date], [Amount in USD], [State], etc.) and populate them with exact, verified data.
   • Attach the detailed nursing study parameters as Exhibit A (Research Proposal) and the milestone payout chart as Schedule 2.

2. Compliance & Signatory Authority Verification:

   • Verify that the designated Principal Investigator holds active nursing credentials and institutional research clearance.
   • Confirm that corporate officers signing on behalf of the Institution possess explicit corporate authority (via board resolution or corporate bylaws) to bind the entity to financial and clinical research obligations.

3. Digital Execution (Signing Phase):

   • Export the finalized, un-bracketed document to a secure PDF format.
   • Upload the PDF to an enterprise-grade digital signature platform compliant with ESIGN and UETA standards (such as DocuSign, Adobe Sign, or HelloSign).
   • Route the document to the authorized signatories in the sequence specified in Section 4. Ensure automated timestamps and audit trails are enabled.

4. Post-Execution Record Retention & Archiving:

   • Upon full execution, download the digitally signed PDF containing the certificate of completion.
   • Archive the master contract within the Institution’s Secure Legal Repository and provide a fully executed copy to the Lead Nurse Researcher.
   • Transmit copies of the executed agreement and approved clinical protocol to the governing Institutional Review Board (IRB) and compliance office for regulatory tracking.